STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

TXG 10X GENOMICS INCORPORATED StockScouter® Report

4

StockScouter® Score

10X GENOMICS INCORPORATED, a mid cap growth company in the healthcare sector, is expected to slightly underperform the market over the next six months with slightly higher than average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • The most recent quarterly earnings report was significantly higher than analysts’ consensus forecast. Positive
  • One or more less experienced analysts has modestly increased quarterly earnings estimates for TXG. Positive/Neutral

 

Concerns

  • The enterprise value-to-sales ratio is much higher than the average for comparably-sized companies in the StockScouter universe. Very Negative
  • Earnings growth in the past year has decelerated moderately compared to earnings growth in the past three years. Negative

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that mid cap stocks will be neutral, growth stocks will be neutral, and healthcare stocks will be neutral.

Expected Risk/Return

Progress: 80% done.
Progress: 40% done.
Low
High

Core Model Grades

A
D
F
D

Previous Ratings

4
4
5